TBPH Theravance Biopharma, Inc.
XNAS 17.04 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TBPH
$17.04
—
Key stats
$17.04
- 52-Week Range
- $13.08 – $21.03
- YTD
- -6.09%
- Straddle Price
- $3.02
- P/C Vol Ratio
- 2.55
- Market Cap
- $0.9B
- Open
- $17.06
- Day Range
- $17.02 – $17.07
- Volume
- 10,043,494
- Prev Close
- $17.03
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.79 |
| Cost of Equity (CAPM) | 8.89% (VRP-adj) |
| WACC | 8.92% |
| Volatility Risk Premium | +248.6pp (IV − HV30) |
| Effective Tax Rate | 16.3% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 18.6% |
| Book / Price | 33.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 48.9% |
| Debt / Equity | 0.00 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | -3.4% (reverse-DCF on current price) |
| SMA 50 | $16.96 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $17.04 |
| Bollinger Width / SMA20 | 2.6% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $1B |
Peers used for multiples: ABT, PFE, REGN
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
88%
20-Day Fair Value
≈ by Oct 23, 2026
$17.36
α +2.0%
rank 35%
conviction
39%
40-Day Fair Value
≈ by Nov 23, 2026
$19.01
α +11.6%
rank 69%
conviction
80%
60-Day Fair Value
≈ by Dec 22, 2026
$19.80
α +16.3%
rank 63%
conviction
88%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $13.15 | 13% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $72.99 | 12% | median 32.7× · 3 peers |
| Peer EV/EBITDA | $7.99 | 12% | median 18.6× · 3 peers |
| Peer P/B | $14.43 | 2% | median 2.5× · 3 peers |
| Peer P/S | $8.14 | 8% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $16.96 | 53% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-09-24 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 90
- List Date
- 2014-05-16
- CIK
- 0001583107
- Headquarters
- George Town, Grand Cayman, CA
- Homepage
- https://www.theravance.com
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human th…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 6.33% | -25.81% | -1.46% | -18.21% | 1.08% | 4.35% | -5.62% |
| Feb | -11.81% | 9.93% | 1.50% | 3.38% | -1.27% | -7.97% | -1.04% |
| Mar | 16.76% | -8.87% | 8.07% | -4.98% | -2.40% | -14.35% | -0.96% |
| Apr | -1.89% | 2.01% | -3.82% | -6.53% | 8.31% | 5.68% | 0.63% |
| May | -12.99% | -13.84% | 1.54% | -2.49% | -11.84% | -4.35% | -7.33% |
| Jun | -16.46% | 5.10% | -7.01% | -0.59% | -1.08% | 6.65% | -2.23% |
| Jul | -9.92% | -9.66% | -5.27% | 18.66% | 2.29% | -0.71% | -0.77% |
| Aug | -39.94% | 3.92% | -3.74% | -17.75% | 27.34% | 1.01% | -4.86% |
| Sep | -10.30% | 7.99% | -12.03% | 0.75% | 5.49% | 0.00% | -1.35% |
| Oct | 4.44% | -0.60% | 8.76% | 0.37% | 1.66% | --* | 2.93% |
| Nov | 4.61% | 7.92% | 6.83% | 11.71% | 33.38% | -- | 12.89% |
| Dec | 28.49% | 3.89% | 5.54% | -0.32% | -4.59% | -- | 6.60% |
| Total | -46.81% | -22.43% | -3.44% | -20.00% | 63.54% | -11.07% | -6.70% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $17.04
SMA 50: $16.96
SMA 200: $17.18
Current: $17.03
EMA 12: $17.03
EMA 26: $17.02
MACD: 0.0182 | Signal: -0.0073
BULLISH
ADX (14): 41.29
STRONG TREND
+DI: 25.17
−DI: 9.63
Momentum Oscillators
RSI (14): 53.24
NEUTRAL
Stoch %K: 14.38
Stoch %D: 13.94
Williams %R: -88.24
Volume & Volatility
BB Upper: $17.08
BB Lower: $17.00
NEUTRAL
OBV: 9,431,887
Vol SMA 20: 1,182,502
Vol ROC: 3700.52%
ATR: $0.06
True Range: $0.05
HV 20: 1.7%
HV 30: 2.4%
HV 60: 3.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-09-25T00:00:00 – 2026-09-23T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: TBPH
Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10) Key Drivers:
- Technical signals indicate a neutral trend, with RSI at 68.81 and MACD in bullish territory.
- Low volatility and beta of 0.54 suggest reduced market risk.
Primary Risks:
- Recent news headlines unavailable; lack of catalysts may lead to sideways trading.
- Options market pricing $2.02 move by expiration, indicating potential for limited price action.
Recent News Sentiment Impact: N/A (no recent news available)
Technical Analysis Trend Direction: NEUTRAL Support/Resistance Levels: + Upper Bollinger Band: $19.61 + Lower Bollinger Band: $12.73 Momentum Signals: + RSI interpretation: Neutral, 68.81 (not overbought or oversold) + MACD signal: Bullish, with a histogram value of 0.87 + Bollinger Bands position: Neutral, indicating no significant trend
Volume Analysis: + Volume SMA 20: $521188.80 + On-Balance Volume (OBV): 10449417.00 + Volume Rate of Change: 114.89%
News & Sentiment Analysis Recent Headlines Summary: N/A (no recent news available) Sentiment Assessment: Neutral Catalyst Identification: None (lack of recent news) Market Narrative: N/A (no recent news available)
Risk & Volatility Assessment Beta Interpretation: Defensive, with a beta of 0.54 relative to SPY Volatility Regime: Low volatility, with an average True Range (ATR) of $0.85 Options Market Signals: + IV Rank: 17.9% (Low) + Current IV: 112.3% + Expected Move: $2.02 (28 DTE), 7-DTE: $3.77 Downside Protection: Support levels at the lower Bollinger Band ($12.73) and potential stop-loss consideration at $15.50
Market Context & Positioning Sector Performance: TBPH relative strength vs sector/market is neutral Institutional Activity: Volume patterns suggest institutional interest, with an OBV value of 10449417.00 Correlation Analysis: Correlation coefficient (R-squared) indicates a moderate relationship between stock and market movements
Key Levels & Action Items Critical Price Levels: + Support: $15.50 (potential stop-loss) + Resistance: $19.61 (upper Bollinger Band)
Breakout/Breakdown Levels: + Breakout above $19.61 for potential uptrend continuation + Breakdown below $12.73 for potential downtrend acceleration
Time-Sensitive Catalysts: None (lack of recent news) Risk Management: Stop-loss consideration at $15.50, with position sizing adjustments based on market conditions
Generated
News
All TBPH news →
Earnings History
20 of 23 under expected move
Avg Expected Move
15.71%
Avg Actual Move
4.25%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-23 | After-Close | 13.03% | 0.91% | 0.07x | Within |
| 2021-05-04 | After-Close | 8.55% | 1.56% | 0.18x | Within |
| 2021-08-03 | After-Close | 21.79% | 4.62% | 0.21x | Within |
| 2021-11-03 | After-Close | 23.14% | 5.20% | 0.22x | Within |
| 2022-02-23 | After-Close | 12.07% | 9.00% | 0.75x | Within |
| 2022-08-04 | After-Close | 14.24% | 7.81% | 0.55x | Within |
| 2022-11-07 | After-Close | 6.47% | 3.08% | 0.48x | Within |
| 2023-01-09 | After-Close | 3.36% | 3.55% | 1.06x | Exceeded |
| 2023-02-27 | After-Close | 8.71% | 2.27% | 0.26x | Within |
| 2023-05-08 | After-Close | 14.21% | 0.44% | 0.03x | Within |
| 2023-08-07 | After-Close | 7.73% | 0.92% | 0.12x | Within |
| 2023-11-07 | After-Close | 7.19% | 5.34% | 0.74x | Within |
| 2024-02-26 | After-Close | 43.12% | 4.98% | 0.12x | Within |
| 2024-05-13 | After-Close | 7.83% | 1.98% | 0.25x | Within |
| 2024-08-05 | After-Close | 9.12% | 18.35% | 2.01x | Exceeded |
| 2024-11-12 | After-Close | 14.31% | 8.64% | 0.60x | Within |
| 2025-02-26 | Pre-Market | 38.74% | 1.23% | 0.03x | Within |
| 2025-05-08 | After-Close | 7.83% | 9.29% | 1.19x | Exceeded |
| 2025-08-12 | Pre-Market | 22.15% | 4.56% | 0.21x | Within |
| 2025-11-10 | Pre-Market | 22.03% | 2.24% | 0.10x | Within |
| 2026-03-18 | After-Close | 18.44% | 1.30% | 0.07x | Within |
| 2026-05-07 | Pre-Market | 8.41% | 0.47% | 0.06x | Within |
| 2026-08-11 | After-Close | 28.96% | 0.00% | 0.00x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TBPH Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $3.02
7-DTE Move: $3.02
Days to Exp: — (2026-10-16)
Options Flow
Call Volume: 208
Put Volume: 531
P/C Volume: 2.553
BEARISH
Call OI: 544
Put OI: 800
P/C OI: 1.471
Total OI: 1,344
ATM Options Pricing
ATM Call: $2.50
ATM Put: $0.53
Call %: 14.7%
Put %: 3.1%
Chain Summary
Chain Volume: 739
Chain OI: 1,344
Last Updated: 10/16/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 51st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
51%
vs own history
GEX tilt
-0.06
OI-weighted, today
Vanna tilt
+0.12
δ-sensitivity to IV
Charm tilt
-0.45
δ-decay vs time
Charm tilt -0.45: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 14 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 14 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$3.02Oct 16
Beta Analysis
Risk Metrics
Beta: 0.4561
Alpha: 23.72%
Correlation: 0.1295
R-Squared: 1.7%
Stock Volatility: 45.9%
Market Volatility: 13.0%
Analysis Details
Benchmark: SPY
Data Points: 228
Period: 252 trading days
Data Points: 228
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TBPH
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $8.6M | #1703 of 6285 | +488.5% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $2.6M | #1819 of 3138 | +20.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.0M | #2591 of 3716 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $8K | #4111 of 4729 | -52.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TBPH Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 51,355,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$243.10K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $243.10K | 100.00% | 2026-06-30 |
5 filers$2.90M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $1.10M | 37.95% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $666.40K | 22.99% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $523.60K | 18.06% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $523.60K | 18.06% | 2026-06-30 |
| 5 | EQUITEC PROPRIETARY MARKETS, LLC | $85.00K | 2.93% | 2026-06-30 |
TBPH Insider Trading (Form 4)
Latest: 2026-09-28Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Andrew M Weiss | Other (J) | −22,371,180 | $17.00 | -$380.31M | EDGAR | |
| 2026-09-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Disp (D) | −189,826 | — | EDGAR | |
| 2026-09-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Disp (D) | −213,476 | — | EDGAR | |
| 2026-09-24 | Donal O'Connor | Director | Disp (D) | −80,213 | — | EDGAR | |
| 2026-09-24 | Deepika Pakianathan | Director | Disp (D) | −64,074 | — | EDGAR | |
| 2026-09-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | Disp (D) | −1,726,989 | — | EDGAR | |
| 2026-09-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Disp (D) | −336,841 | — | EDGAR | |
| 2026-09-24 | Susannah Gray | Director | Disp (D) | −48,146 | — | EDGAR | |
| 2026-09-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Disp (D) | −355,168 | — | EDGAR | |
| 2026-09-24 | Alsup Laurie Smaldone | Director | Disp (D) | −80,989 | — | EDGAR | |
| 2026-09-24 | Dean J Mitchell | Director | Disp (D) | −97,213 | — | EDGAR | |
| 2026-09-17 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell (S) | −13,314 | $17.03 | -$226.8K | EDGAR |
| 2026-08-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Tax (F) | −8,112 | $16.95 | -$137.5K | EDGAR |
| 2026-08-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Tax (F) | −6,258 | $16.95 | -$106.1K | EDGAR |
| 2026-08-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Tax (F) | −5,667 | $16.95 | -$96.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TBPH Insider Holdings
9 insiders · @ $17.03
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Eli Samaha | 10%+ Owner | 9,167,489 | $156.12M | $15.00M | 4 | 2026-07-08 |
| 2 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | 89,062 | $1.52M | -$2.12M | 39 | 2026-09-24 |
| 3 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | 76,875 | $1.31M | $634.4K | 63 | 2026-09-24 |
| 4 | Eran Broshy | Director | 60,204 | $1.03M | -$2.47M | 14 | 2025-12-01 |
| 5 | Jeremy T Grant | Director | 32,954 | $561.2K | $0 | 3 | 2025-05-21 |
| 6 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | 23,439 | $399.2K | $0 | 20 | 2026-09-24 |
| 7 | Dean J Mitchell | Director | 6,009 | $102.3K | $0 | 13 | 2026-09-24 |
| 8 | Deepika Pakianathan | Director | 6,009 | $102.3K | $0 | 8 | 2026-09-24 |
| 9 | Susannah Gray | Director | 6,009 | $102.3K | $0 | 6 | 2026-09-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TBPH Board & Officers
As of SEC filings through Sep 28, 2026Directors 2
- Eran Broshy · since Jun 3, 2014
- Jeremy T Grant · since Dec 21, 2023
10% owners 1
- Eli Samaha · since Sep 20, 2022
Changes in the last 10 years (41)
| Sep 28, 2026 | Weiss Asset Management LP reported in an SEC filing no longer being a 10% owner |
| Sep 28, 2026 | Wam Gp LLC reported in an SEC filing no longer being a 10% owner |
| Sep 28, 2026 | Andrew M Weiss reported in an SEC filing no longer being a 10% owner |
| Sep 24, 2026 | Susannah Gray reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Rick E Winningham reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Rick E Winningham reported in an SEC filing no longer being Chief Executive Officer |
| Sep 24, 2026 | Rhonda Farnum reported in an SEC filing no longer being SVP, Comm & Medical Affairs |
| Sep 24, 2026 | Donal O'Connor reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Deepika Pakianathan reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Dean J Mitchell reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Brett A. Grimaud reported in an SEC filing no longer being SVP, Gen Counsel and Secretary |
| Sep 24, 2026 | Aziz Sawaf reported in an SEC filing no longer being SVP & Chief Financial Officer |
| Sep 24, 2026 | Alsup Laurie Smaldone reported in an SEC filing no longer being a director |
| Sep 24, 2026 | Aine Miller reported in an SEC filing no longer being SVP, Dev & Head of Ire Office |
| Feb 6, 2024 | Aine Miller became SVP, Dev & Head of Ire Office |
| Dec 21, 2023 | Jeremy T Grant became a director |
| Apr 11, 2023 | James Connor Kelly became a director |
| Feb 26, 2023 | The company announced the departure of William D Young from the board in an SEC filing |
| Feb 26, 2023 | Susannah Gray became a director |
| Feb 14, 2023 | Brett A. Grimaud became SVP, Gen Counsel and Secretary |
| Jan 1, 2023 | Aziz Sawaf became SVP & Chief Financial Officer |
| Dec 9, 2022 | The company announced the departure of Andrew A. Hindman as SVP, Chief Financial Officer in an SEC filing |
| Nov 17, 2022 | Richard A Graham listed as SVP, Research & Development (previously SVP, Development) in SEC filings |
| Sep 20, 2022 | Eli Samaha became a 10% owner |
| Sep 19, 2022 | Weiss Asset Management LP became a 10% owner |
| Sep 19, 2022 | Wam Gp LLC became a 10% owner |
| Sep 19, 2022 | Andrew M Weiss became a 10% owner |
| Dec 1, 2021 | Rhonda Farnum became SVP, Comm & Medical Affairs |
| Nov 30, 2021 | The company announced the departure of Vijay Sabesan as SVP, Technical Operations in an SEC filing |
| Feb 10, 2021 | Frank Pasqualone listed as SVP, Chief Business Officer (previously SVP, Chief Comm Ops Officer) in SEC filings |
| Aug 24, 2020 | Brett K Haumann listed as Chief Medical Officer (previously SVP Clin Dev & Chief Med Ofc) in SEC filings |
| Aug 3, 2020 | Richard A Graham became SVP, Development |
| Jul 1, 2020 | Deepika Pakianathan became a director |
| Nov 22, 2019 | Philip D Worboys listed as SVP, Research & Transl Science (previously SVP, Translational Science) in SEC filings |
| Jun 3, 2019 | Andrew A. Hindman became SVP, Chief Financial Officer |
| Feb 6, 2019 | Vijay Sabesan became SVP, Technical Operations |
| Feb 6, 2019 | Ann Brady became President, TBIL |
| Feb 13, 2018 | Alsup Laurie Smaldone became a director |
| Aug 1, 2017 | Shehnaaz Suliman became SVP, Corp Dev & Strategy |
| May 23, 2017 | Frank Pasqualone listed as SVP, Chief Comm Ops Officer (previously SVP Global Head Acute Care Bus) in SEC filings |
| Feb 8, 2017 | Frank Pasqualone listed as SVP Global Head Acute Care Bus (previously Sr. VP, Operations) in SEC filings |
Not reported recently (19)
- James Connor Kelly · Last reported as a director in an SEC filing dated May 8, 2024
- Richard A Graham · Last reported as SVP, Research & Development in an SEC filing dated Feb 22, 2024
- Burton G Malkiel · Last reported as a director in an SEC filing dated May 4, 2023
- Kenneth R Pitzer · Last reported as SVP, Prod Strat & Comm Plng in an SEC filing dated Feb 23, 2022
- Ann Brady · Last reported as President, TBIL in an SEC filing dated Feb 23, 2022
- Frank Pasqualone · Last reported as SVP, Chief Business Officer in an SEC filing dated Nov 23, 2021
- Philip D Worboys · Last reported as SVP, Research & Transl Science in an SEC filing dated Nov 23, 2021
- Bradford J Shafer · Last reported as EVP, Gen. Counsel, Secretary in an SEC filing dated Aug 24, 2021
- George M Whitesides · Last reported as a director in an SEC filing dated Apr 29, 2021
- Robert V Gunderson JR · Last reported as a director in an SEC filing dated Apr 29, 2021
- Susan Molineaux · Last reported as a director in an SEC filing dated Apr 29, 2021
- Brett K Haumann · Last reported as Chief Medical Officer in an SEC filing dated Feb 23, 2021
- Gsk Plc · Last reported as a 10% owner in an SEC filing dated Jun 22, 2020
- Sharathchandra S Hegde · Last reported as SVP, Research in an SEC filing dated Aug 22, 2019
- Peter S Ringrose · Last reported as a director in an SEC filing dated May 2, 2019
- Shehnaaz Suliman · Last reported as SVP, Corp Dev & Strategy in an SEC filing dated Feb 22, 2019
- Renee D Gala · Last reported as SVP, Chief Financial Officer in an SEC filing dated Nov 21, 2018
- Henrietta Fore · Last reported as a director in an SEC filing dated Aug 11, 2017
- Junning Lee · Last reported as Sr. VP, Technical Operations in an SEC filing dated Feb 22, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TBPH Proposed Insider Sales (Form 144)
Latest: 2026-09-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $227K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
RHONDA FARNUM (1, $227K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | RHONDA FARNUM | Officer | 13,314 | $226.8K | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-15 | RHONDA FARNUM | Officer | 13,314 | $218.2K | 2026-06-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-16 | RHONDA FARNUM | Officer | 31,067 | $433.6K | 2026-03-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-03 | RHONDA FARNUM | Officer | 31,067 | $582.5K | 2025-12-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-26 | ERAN BROSHY | Director | 29,501 | $590.0K | 2025-11-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-12 | ERAN BROSHY | Director | 45,000 | $809.2K | 2025-11-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-07-14 | RHONDA FARNUM | Officer | 10,000 | $113.9K | 2025-07-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-06-02 | RHONDA FARNUM | Officer | 24,000 | $264.0K | 2025-06-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-01-21 | RHONDA FARNUM | Officer | 4,000 | $36.0K | 2025-01-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-11-14 | RICHARD A GRAHAM | Officer | 2,482 | $25.4K | 2023-11-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
4 ETFs hold TBPH
4 shown · $1.96M total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.52% | $838,814 | — | 2026-05-31 |
| 2 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.05% | $619,875 | — | 2026-07-31 |
| 3 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $477,947 | — | 2026-07-31 |
| 4 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $21,553 | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$2.23
TTM Revenue
$109.78M
TTM Net Income
$114.53M
TTM Op. Cash Flow
$268.78M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $17.70M | $-4.93M | $-0.10 | $73.28M |
| Q4 '25 | 2025-12-31 | $45.89M | $61.02M | $1.18 | $-6.06M |
| Q3 '25 | 2025-09-30 | $19.99M | $3.62M | $0.07 | $-6.51M |
| Q2 '25 | 2025-06-30 | $26.20M | $54.83M | $1.08 | $208.07M |
| Q1 '25 | 2025-03-31 | $15.39M | $-13.58M | $-0.27 | $43.04M |
| Q4 '24 | 2024-12-31 | $18.75M | $-15.53M | $-0.31 | $-902.00K |
| Q3 '24 | 2024-09-30 | $16.87M | $-12.70M | $-0.26 | $-5.20M |
| Q2 '24 | 2024-06-30 | $14.26M | $-16.51M | $-0.34 | $-4.42M |
| Q1 '24 | 2024-03-31 | $14.50M | $-11.66M | $-0.24 | $-1.02M |
| Q4 '23 | 2023-12-31 | $17.57M | $-8.51M | $-0.19 | $-854.00K |
| Q3 '23 | 2023-09-30 | $15.69M | $-8.95M | $-0.17 | $-2.49M |
| Q2 '23 | 2023-06-30 | $13.75M | $-15.64M | $-0.28 | $-12.44M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
0.00
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
39.4%
ROA
24.2%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-09-24
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.69M
SI % of Float
4.53%
Days to Cover
4.50
Short Vol Ratio
34.6%
Free Float
37.20M
Float %
71.7%
Short interest 2026-09-15 • Short volume 2026-09-23 • Float 2026-08-14